The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.
This feature is a deep dive into the challenges of defining and treating Difficult-to-Treat Rheumatoid Arthritis (D2T-RA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback